Medindia

X

Accuray Announces Results for Third Quarter of Fiscal 2011

Friday, May 6, 2011 General News J E 4
Advertisement

Accuray Incorporated

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

March 31,

June 30,

2011

2010

Assets

Current assets:

Cash and cash equivalents

$  57,332

$  45,434

Restricted cash

22

22

Short-term available-for-sale securities

85,603

99,881

Accounts receivable, net of allowance for doubtful accounts of $225 and $115 at  

      March 31, 2011 and June 30, 2010, respectively

44,871

37,955

Inventories

34,408

28,186

Prepaid expenses and other current assets

9,150

19,356

Deferred cost of revenue—current

5,131

7,889

Total current assets

236,517

238,723

Deferred cost of revenue—noncurrent

2,193

3,213

Property and equipment, net

16,514

14,684

Goodwill

4,495

4,495

Intangible assets, net

194

388

Other assets

1,816

1,681

Total assets

$261,729

$263,184

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$    9,873

$  10,317

Accrued compensation

9,941

10,786

Other accrued liabilities

7,881

10,669

Customer advances

13,484

12,884

Deferred revenue—current

35,626

42,019

Total current liabilities

76,805

86,675

Long-term other liabilities

999

1,059

Deferred revenue—noncurrent

4,655

5,374

Total liabilities

82,459

93,108

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding

Common stock, $0.001 par value; authorized: 100,000,000 shares; issued: 62,291,644 and 60,666,974 shares at March 31, 2011 and June 30, 2010, respectively; outstanding: 60,151,626 and 58,526,956 shares at March 31, 2011 and June 30, 2010, respectively

60

59

Additional paid-in capital

298,530

287,764

Accumulated other comprehensive income (loss)

85

(71)

Accumulated deficit

(119,405)

(117,676)

Total stockholders’ equity

179,270

170,076

Total liabilities and stockholders’ equity

$261,729

$263,184

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PEDIATRX RELEASES DATA ON COPAY ASSISTANCE PROGRAM...
S
Amylin Pharmaceuticals to Present at the Bank of A...